Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study

Research output: Contribution to journalArticle

Abstract

Background/Aims: Recent findings suggest an involvement of insulin-like growth factor-1 (IGF-1) in the pathogenesis of many psychiatric disorders; however, there is a lack of data regarding IGF-1 in patients with obsessive-compulsive disorder (OCD). The aims of the present study were (1) to analyze putative alterations of IGF-1 serum content in patients with OCD compared to patients with major depressive disorder (MDD) and healthy controls, and (2) to analyze putative changes of IGF-1 levels during drug treatment in subjects with OCD compared to patients with MDD. Methods: We recruited 40 OCD patients, 37 MDD patients, and 43 healthy controls. All participants were adults. Serum IGF-1 levels were measured by the ELISA method on venous blood samples collected at baseline and after 10 ± 1 weeks of drug treatment. Results: IGF-1 levels were increased in OCD patients compared to controls (149.9 ± 60.2 vs. 121.2 ± 51.6 ng/ml; p = 0.040). No correlations were observed between baseline IGF-1 levels, clinical features, and response to treatment at follow-up in OCD or MDD patients. No changes in serum IGF-1 were observed after drug treatment. Conclusion: Our results show for the first time that serum IGF-1 levels are altered in patients with OCD. Further research on the role of IGF-1 in OCD is warranted.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalNeuropsychobiology
Volume74
DOIs
Publication statusPublished - 2016

Fingerprint

Obsessive-Compulsive Disorder
Somatomedins
Case-Control Studies
Serum
Major Depressive Disorder
Pharmaceutical Preparations
Therapeutics
Psychiatry
Enzyme-Linked Immunosorbent Assay

Keywords

  • Antidepressants
  • Depression
  • Growth hormone
  • Insulin-like growth factor-1
  • Neurobiology
  • Neurotrophic factors
  • Obsessive-compulsive disorder
  • Serotonin reuptake inhibitors
  • Somatotropic axis
  • Treatment response

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuropsychology and Physiological Psychology
  • Biological Psychiatry

Cite this

@article{d270d1b603f0466aa52e71d9209ad0e1,
title = "Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study",
abstract = "Background/Aims: Recent findings suggest an involvement of insulin-like growth factor-1 (IGF-1) in the pathogenesis of many psychiatric disorders; however, there is a lack of data regarding IGF-1 in patients with obsessive-compulsive disorder (OCD). The aims of the present study were (1) to analyze putative alterations of IGF-1 serum content in patients with OCD compared to patients with major depressive disorder (MDD) and healthy controls, and (2) to analyze putative changes of IGF-1 levels during drug treatment in subjects with OCD compared to patients with MDD. Methods: We recruited 40 OCD patients, 37 MDD patients, and 43 healthy controls. All participants were adults. Serum IGF-1 levels were measured by the ELISA method on venous blood samples collected at baseline and after 10 ± 1 weeks of drug treatment. Results: IGF-1 levels were increased in OCD patients compared to controls (149.9 ± 60.2 vs. 121.2 ± 51.6 ng/ml; p = 0.040). No correlations were observed between baseline IGF-1 levels, clinical features, and response to treatment at follow-up in OCD or MDD patients. No changes in serum IGF-1 were observed after drug treatment. Conclusion: Our results show for the first time that serum IGF-1 levels are altered in patients with OCD. Further research on the role of IGF-1 in OCD is warranted.",
keywords = "Antidepressants, Depression, Growth hormone, Insulin-like growth factor-1, Neurobiology, Neurotrophic factors, Obsessive-compulsive disorder, Serotonin reuptake inhibitors, Somatotropic axis, Treatment response",
author = "Gianluca Rosso and Roberta Zanardini and Chiodelli, {Daniela Francesca} and Clarissa Ferrari and Massimo Gennarelli and Luisella Bocchio-Chiavetto",
year = "2016",
doi = "10.1159/000446918",
language = "English",
volume = "74",
pages = "15--21",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder

T2 - A Case-Control Study

AU - Rosso, Gianluca

AU - Zanardini, Roberta

AU - Chiodelli, Daniela Francesca

AU - Ferrari, Clarissa

AU - Gennarelli, Massimo

AU - Bocchio-Chiavetto, Luisella

PY - 2016

Y1 - 2016

N2 - Background/Aims: Recent findings suggest an involvement of insulin-like growth factor-1 (IGF-1) in the pathogenesis of many psychiatric disorders; however, there is a lack of data regarding IGF-1 in patients with obsessive-compulsive disorder (OCD). The aims of the present study were (1) to analyze putative alterations of IGF-1 serum content in patients with OCD compared to patients with major depressive disorder (MDD) and healthy controls, and (2) to analyze putative changes of IGF-1 levels during drug treatment in subjects with OCD compared to patients with MDD. Methods: We recruited 40 OCD patients, 37 MDD patients, and 43 healthy controls. All participants were adults. Serum IGF-1 levels were measured by the ELISA method on venous blood samples collected at baseline and after 10 ± 1 weeks of drug treatment. Results: IGF-1 levels were increased in OCD patients compared to controls (149.9 ± 60.2 vs. 121.2 ± 51.6 ng/ml; p = 0.040). No correlations were observed between baseline IGF-1 levels, clinical features, and response to treatment at follow-up in OCD or MDD patients. No changes in serum IGF-1 were observed after drug treatment. Conclusion: Our results show for the first time that serum IGF-1 levels are altered in patients with OCD. Further research on the role of IGF-1 in OCD is warranted.

AB - Background/Aims: Recent findings suggest an involvement of insulin-like growth factor-1 (IGF-1) in the pathogenesis of many psychiatric disorders; however, there is a lack of data regarding IGF-1 in patients with obsessive-compulsive disorder (OCD). The aims of the present study were (1) to analyze putative alterations of IGF-1 serum content in patients with OCD compared to patients with major depressive disorder (MDD) and healthy controls, and (2) to analyze putative changes of IGF-1 levels during drug treatment in subjects with OCD compared to patients with MDD. Methods: We recruited 40 OCD patients, 37 MDD patients, and 43 healthy controls. All participants were adults. Serum IGF-1 levels were measured by the ELISA method on venous blood samples collected at baseline and after 10 ± 1 weeks of drug treatment. Results: IGF-1 levels were increased in OCD patients compared to controls (149.9 ± 60.2 vs. 121.2 ± 51.6 ng/ml; p = 0.040). No correlations were observed between baseline IGF-1 levels, clinical features, and response to treatment at follow-up in OCD or MDD patients. No changes in serum IGF-1 were observed after drug treatment. Conclusion: Our results show for the first time that serum IGF-1 levels are altered in patients with OCD. Further research on the role of IGF-1 in OCD is warranted.

KW - Antidepressants

KW - Depression

KW - Growth hormone

KW - Insulin-like growth factor-1

KW - Neurobiology

KW - Neurotrophic factors

KW - Obsessive-compulsive disorder

KW - Serotonin reuptake inhibitors

KW - Somatotropic axis

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84980383585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980383585&partnerID=8YFLogxK

U2 - 10.1159/000446918

DO - 10.1159/000446918

M3 - Article

AN - SCOPUS:84980383585

VL - 74

SP - 15

EP - 21

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

ER -